Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 729

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 729
---
 Statements of Stockholders’ Deficit for the years ended December 31, 2024 and 2023                         |     |      | F-67 |
| Statements of Cash Flows for the years ended December 31, 2024 and 2023                                    |     |      | F-68 |
| Notes to the Financial Statements                                                                          |     |      | F-69 |
| UNAUDITED CONDENSED FINANCIAL STATEMENTS:                                                                  |     |      |      |
| Unaudited Condensed Balance Sheets as of March 31, 2025 and December 31, 2024                              |     |      | F-85 |
| Unaudited Condensed Statements of Operations for the three months ended March 31, 2025 and 2024            |     |      | F-86 |
| Unaudited Condensed Statements of Stockholders’ Deficit for the three months ended March 31, 2025 and 2024 |     |      | F-87 |
| Unaudited Condensed Statements of Cash Flows for the three months ended March 31, 2025 and 2024            |     |      | F-88 |
| Notes to the Unaudited Condensed Financial Statements                                                      |     |      | F-89 |

F-1

<div align='center'>**Report of Independent Registered Public Accounting Firm**</div>

To the Shareholders and Board of Directors of

Denali Capital Acquisition Corp.

### Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheet of Denali Capital Acquisition Corp. (the “Company”) as of December 31, 2024, the related consolidated statements of operations, shareholders’ deficit and cash flows for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, based on our audit, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 9 to the financial statements, the Company adopted ASU 2023-07, Segment Reporting (Topic 280) as of December 31, 2024. We also have audited the adjustments necessary to restate the 2023 segment information and to